BillionToOne reported a sharp jump in Q1 2026 revenue, driven by increased prenatal clinical testing volume. Revenue rose 84% year over year to $108.4 million, while prenatal testing contributed $96.5 million. The company said it accessioned 189,000 tests in Q1, up 38% from a year earlier, and delivered 188,000 tests in the quarter. BillionToOne also highlighted the launch of Unity Confirm, a non-invasive circulating fetal cell-based assay intended to confirm high-risk prenatal screening results without procedures such as CVS or amniocentesis.